Fig. 1

Increased expression levels of IL-17A in patients with CRC. A Differentially expressed IL-17A between tumour and normal tissues; ACC: Adrenocortical carcinoma; BLCA: Bladder Urothelial Carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; DLBC: Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC: Head and Neck squamous cell carcinoma; KICH: Kidney Chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LAML: Acute Myeloid Leukemia; LGG: Brain Lower Grade Glioma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; OV: Ovarian serous cystadenocarcinoma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and Paraganglioma; PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; SARC: Sarcomav; SKCM: Skin Cutaneous. Melanoma B Differentially expressed IL-17A between colorectal tumour and normal tissues; C Comparison of overall survival in IL-17A high and IL-17A low groups; D-E Representative western blot and quantification analysis of IL-17A expression in paired CRC samples. Data conforms to normal distribution, and tested by two independent samples t-test; F Immunohistochemical results showing expression of IL-17A in colorectal tumour and normal tissues; G Comparison of overall survival in IL-17A high and IL-17A low groups